Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 3Keratosis, Actinic 3Carcinoma, Basal Cell 3Urinary Bladder Neoplasms 2Skin Neoplasms 2Lymphoma, Non-Hodgkin 2Glioblastoma 2Carcinoma, Squamous Cell 2Stomatitis 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell 1Lymphoma 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hodgkin Disease 1Head and Neck Neoplasms 1Depression 1Deglutition Disorders 1Carcinoma, Non-Small-Cell Lung 1Anxiety Disorders 1

Interventions

Therapeutics 31Psychiatric Rehabilitation 27Surveys and Questionnaires 15Cognitive Behavioral Therapy 12Early Intervention, Educational 10Psilocybin 9Ketamine 9Methods 8Saline Solution 7Yoga 6Mindfulness-Based Cognitive Therapy 6Interviews as Topic 6Esketamine 6Counseling 6Psychosocial Intervention 5Mindfulness 5Methylphenidate 5Escitalopram 5Educational Status 5Behavior Therapy 5Acupuncture Therapy 5Palliative Care 4Exercise Therapy 4Exercise 4Control Groups 4Caregivers 4Standard of Care 3Psychotherapy 3Niacin 3Mindfulness-Based Stress Reduction 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Depression × Niacinamide × Clear all
NCT00302744 2025-03-13

Effects of Psilocybin in Advanced-Stage Cancer Patients With Anxiety

Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

Phase 1/2 Completed
12 enrolled

Anxiety Disorders, Depression, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡